We are live on ! Find out more
O

OrbiMed Portfolio holdings

AUM $5.05B
1-Year Est. Return 125.28%
This Fund
S&P 500
This Quarter Est. Return
+18.47%
1 Year Est. Return
+125.28%
3 Year Est. Return
+334.72%
5 Year Est. Return
+344.07%
10 Year Est. Return
+2,748.76%
AUM
$5.6B
AUM Growth
+$886M
Cap. Flow
+$142M
Cap. Flow %
2.54%
Top 10 Hldgs %
40.08%
Holding
154
New
29
Increased
38
Reduced
31
Closed
27

Top Buys

Rank Stock Value
1
MRK icon
Merck
MRK
+$93.3M
2
BMY icon
Bristol-Myers Squibb
BMY
+$82.6M
3
SHPG
Shire pic
SHPG
+$76.4M
4
SPY icon
State Street SPDR S&P 500 ETF Trust
SPY
+$50.3M
5
CBST
CUBIST PHARMACEUTICALS INC
CBST
+$49.2M

Top Sells

Rank Stock Value
1
ONXX
ONYX PHARMACEUTICALS INC
ONXX
+$149M
2
INCY icon
Incyte
INCY
+$33.4M
3
MAKO
MAKO SURGICAL CORP COM
MAKO
+$26.7M
4
PFE icon
Pfizer
PFE
+$25.6M
5
AGN
Allergan plc
AGN
+$23.7M

Sector Composition

Rank Sector Weight
1 Healthcare 83.56%
2 Financials 1.77%
3 Technology 0.15%
4 Utilities 0%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
QCOR
101
DELISTED
QUESTCOR PHARMA INC
QCOR
$4.64M 0.08%
80,000
– –
SYK icon
102
Stryker
SYK
$134B
$4.46M 0.08%
66,000
-48,800
-43% -$3.37M
BCR
103
DELISTED
CR Bard Inc.
BCR
$4.38M 0.08%
38,000
– –
AEGR
104
PUT
DELISTED
Aegerion Pharmaceuticals
AEGR
$4.29M 0.08%
+50,000
New +$4.24M
CVD
105
DELISTED
COVANCE INC.
CVD
$4.15M 0.07%
48,000
– –
VPHM
106
PUT
DELISTED
VIROPHARMA INC
VPHM
$3.93M 0.07%
+100,000
New +$3.27M
AMRN
107
Amarin Corp
AMRN
$300M
$3.79M 0.07%
30,000
– –
ANTH
108
DELISTED
Anthera Pharmaceuticals, Inc.
ANTH
$3.75M 0.07%
116,594
– –
ZBH icon
109
Zimmer Biomet
ZBH
$18.6B
$3.7M 0.07%
46,350
-37,389
-45% -$2.94M
EW icon
110
Edwards Lifesciences
EW
$49B
$3.48M 0.06%
300,000
– –
MDVN
111
PUT
DELISTED
MEDIVATION, INC.
MDVN
$3M 0.05%
+100,000
New +$2.85M
BLRX
112
BioLineRX
BLRX
$12.3M
$2.92M 0.05%
2,225
-424
-16% -$501K
CELGZ
113
DELISTED
Celgene Corporation Contingent Value Rights
CELGZ
$2.9M 0.05%
360,900
-139,100
-28% -$1.07M
ALBO
114
DELISTED
Albireo Pharma Inc
ALBO
$2.83M 0.05%
29,915
-59,763
-67% -$7.78M
QLTI
115
DELISTED
QLT Inc
QLTI
$2.78M 0.05%
600,000
+37,000
+7% +$161K
INFI
116
CALL
DELISTED
Infinity Pharmaceuticals, Inc.
INFI
$2.62M 0.05%
+150,000
New +$2.87M
DNDN
117
DELISTED
DENDREON CORPORATION
DNDN
$2.54M 0.05%
868,000
-3,234,300
-79% -$12M
KERX
118
CALL
DELISTED
Keryx Biopharmaceuticals Inc
KERX
$2.52M 0.05%
+250,000
New +$2.22M
BSX icon
119
Boston Scientific
BSX
$68.7B
$2M 0.04%
+170,000
New +$1.84M
VNDA icon
120
PUT
Vanda Pharmaceuticals
VNDA
$301M
$1.53M 0.03%
+139,400
New +$1.49M
XTNT icon
121
Xtant Medical Holdings
XTNT
$57.7M
$1.18M 0.02%
14,620
– –
ESPR
122
DELISTED
Esperion Therapeutics
ESPR
$1.15M 0.02%
+60,800
New +$1.02M
WX
123
DELISTED
WUXI PHARMATECH, CAYMAN INC REPSTG 8 ORD SHS
WX
$863K 0.02%
+31,500
New +$746K
MYGN icon
124
PUT
Myriad Genetics
MYGN
$488M
$705K 0.01%
+30,000
New +$852K
CHDX
125
DELISTED
CHINDEX INTL INC
CHDX
$545K 0.01%
32,000
– –
3 4
5
6 7

Similar funds

HSA
HBK Sorce Advisory Erie, Pennsylvania $5.05B AUM 16.64% 1-Year Est. Return
NL
NEPC LLC Boston, Massachusetts $5.02B AUM 7.87% 1-Year Est. Return
BPWM
Badgley Phelps Wealth Managers Seattle, Washington $5.02B AUM 21.87% 1-Year Est. Return
LFG
Lazard Frères Gestion Paris, France $5.07B AUM 20.66% 1-Year Est. Return
JIM
Jensen Investment Management Lake Oswego, Oregon $5.07B AUM 4.98% 1-Year Est. Return
CTC
Central Trust Company Jefferson City, Missouri $5.08B AUM 25.65% 1-Year Est. Return
PAMP
Polar Asset Management Partners Toronto, Ontario, Canada $5.01B AUM 35.27% 1-Year Est. Return
SGM
Skye Global Management West Palm Beach, Florida $5B AUM 11.9% 1-Year Est. Return

OrbiMed's Q3 2013 Portfolio in Review

As of Q3 2013, OrbiMed held 154 positions worth $5.6B, up 19% from $4.72B the previous quarter. Its ten largest holdings account for 40% of the portfolio.

OrbiMed's Q3 2013 filing shows 29 new, 38 increased, 31 reduced and 27 closed positions. Its largest new stake was Shire pic: 690,900 shares worth $82.8M. The largest sale was ONYX PHARMACEUTICALS INC, an estimated $149M.

By sector, the portfolio is most concentrated in Healthcare at 84% of assets, up from 80% a quarter earlier, followed by Financials and Technology.

  • OrbiMed's largest Q3 2013 buy was Shire pic: 690,900 shares worth $82.8M.
  • OrbiMed added most to Merck in Q3 2013, an estimated $93.3M increase.
  • OrbiMed's biggest Q3 2013 reduction was Incyte, cutting an estimated $33.4M.
  • OrbiMed fully exited ONYX PHARMACEUTICALS INC in Q3 2013, selling an estimated $149M.
  • OrbiMed's ten largest holdings make up 40% of its $5.6B portfolio in Q3 2013.
  • OrbiMed opened 29 new positions and closed 27 in Q3 2013.
  • OrbiMed's portfolio value rose 19% quarter-over-quarter to $5.6B.

Based on OrbiMed's 13F filing for Q3 2013, filed 14 Nov 2013.